Skip to Content


With new CEO and McKesson veteran Brian Tyler at the helm, the nation’s largest drug distributor recorded 2.9% revenue growth, fueled largely by more sales and higher drug prices, as well as acquisitions. That growth offset the loss of some customers and the price declines of branded drugs going off-patent. The company, which delivers a third of the nation’s drugs and counts Walmart as a customer, saw profits drop due to a variety of impairment charges and costs associated with opioid-related litigation. Along with other drug distributors, McKesson is the subject of a federal criminal investigation and is fighting thousands of lawsuits over its alleged role in the nation’s opioid epidemic. In February, 21 states rejected a proposed $18 billion settlement with McKesson and the U.S.’s two other largest drug wholesalers.
Courtesy of McKesson
Lists ranking McKesson
Fortune 500 - 2020This year's Fortune 500 marks the 66th running of ...READ MORE
World’s Most Admired Companies - 2020For an astounding 13th straight year, Apple claims...READ MORE
Global 500 - 2019This year's Global 500 generated $27.7 trillion in...READ MORE
Created with sketchtool.Created with sketchtool.Leads, insights, and financial data for the FORTUNE 500, FORTUNE 1000, and Global 500 companies.Purchase Now